NO2118279T3 - - Google Patents
Info
- Publication number
- NO2118279T3 NO2118279T3 NO08727718A NO08727718A NO2118279T3 NO 2118279 T3 NO2118279 T3 NO 2118279T3 NO 08727718 A NO08727718 A NO 08727718A NO 08727718 A NO08727718 A NO 08727718A NO 2118279 T3 NO2118279 T3 NO 2118279T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88521207P | 2007-01-16 | 2007-01-16 | |
PCT/US2008/051123 WO2008089212A1 (fr) | 2007-01-16 | 2008-01-16 | Nouvelle composition pour le traitement du syndrome métabolique |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2118279T3 true NO2118279T3 (fr) | 2018-04-21 |
Family
ID=39636359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO08727718A NO2118279T3 (fr) | 2007-01-16 | 2008-01-16 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8431552B2 (fr) |
EP (2) | EP2118279B1 (fr) |
JP (1) | JP5271918B2 (fr) |
KR (1) | KR101460820B1 (fr) |
CN (1) | CN101631859B (fr) |
AR (1) | AR065837A1 (fr) |
AU (1) | AU2008206328B2 (fr) |
BR (1) | BRPI0806774A2 (fr) |
CA (1) | CA2675638C (fr) |
DK (1) | DK2118279T3 (fr) |
ES (1) | ES2660173T3 (fr) |
IL (1) | IL199903A (fr) |
MX (1) | MX2009007720A (fr) |
MY (1) | MY154869A (fr) |
NO (1) | NO2118279T3 (fr) |
NZ (1) | NZ578891A (fr) |
RU (1) | RU2486902C2 (fr) |
SG (1) | SG178716A1 (fr) |
TR (1) | TR201802359T4 (fr) |
TW (2) | TWI440456B (fr) |
WO (1) | WO2008089212A1 (fr) |
ZA (1) | ZA200904972B (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007041643A1 (fr) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Calcium alimentaire pour reduire la production d'especes d'oxygene reactives |
EP2124985A4 (fr) * | 2007-01-26 | 2011-06-08 | Univ Washington | Méthodes et compositions destinées au traitement de neuropathies |
CA2724023C (fr) * | 2008-05-13 | 2014-02-18 | Genmedica Therapeutics Sl | Conjugues de salicyles utiles pour le traitement de troubles metaboliques |
CA2666036C (fr) * | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Compositions inedites et methodes de traitement des maladies hyperproliferantes |
WO2010053949A1 (fr) * | 2008-11-04 | 2010-05-14 | Metaproteomics, Llc | Compositions phytochimiques et procédés d'activation de l'amp kinase |
KR100922519B1 (ko) * | 2008-11-12 | 2009-10-20 | 대원제약주식회사 | 펠루비프로펜을 함유하는 용출률 및 안정성이 개선된 경구투여용 약제학적 제제 |
US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
CA2755069A1 (fr) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Conjugues anti-inflammatoires et anti-oxydants utiles pour traiter des troubles metaboliques |
EP2408434A4 (fr) * | 2009-03-16 | 2013-11-27 | Ipintl Llc | Traitement de la maladie d'alzheimer et de l'ostéoporose, et réduction du vieillissement |
US8486922B2 (en) * | 2010-04-28 | 2013-07-16 | Chien-Hung Chen | Composition |
US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
EP2705842A1 (fr) * | 2012-09-05 | 2014-03-12 | Pharnext | Approches thérapeutiques pour le traitement de la maladie de Parkinson |
WO2013012760A1 (fr) | 2011-07-15 | 2013-01-24 | Numeta Sciences, Inc. | Compositions et procédés de modulation de voies métaboliques |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
CA2872012C (fr) * | 2012-05-08 | 2017-06-20 | Aeromics, Llc | Nouveaux procedes |
US20140024708A1 (en) * | 2012-07-17 | 2014-01-23 | Banavara L. Mylari | Ursolic acid salts for treating diabetes and obesity |
US9636329B2 (en) * | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
AU2013344753B2 (en) | 2012-11-13 | 2018-09-27 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
US10653779B2 (en) | 2013-03-13 | 2020-05-19 | Genentech, Inc. | Formulations with reduced oxidation |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
RS57813B1 (sr) * | 2013-03-13 | 2018-12-31 | Hoffmann La Roche | Formulacije sa smanjenom oksidacijom |
JP6550370B2 (ja) | 2013-03-15 | 2019-07-24 | ニューサート サイエンシーズ, インコーポレイテッド | 脂質レベルを低下させるロイシンおよびニコチン酸 |
CN105636438A (zh) * | 2013-03-15 | 2016-06-01 | 陈建宏 | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 |
SG11201604153UA (en) | 2013-11-06 | 2016-07-28 | Aeromics Inc | Novel formulations |
MX2016011063A (es) | 2014-02-27 | 2016-11-30 | Nusirt Sciences Inc | Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica. |
MY181685A (en) | 2014-05-05 | 2020-12-31 | Univ Texas | Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer |
US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
US20180228818A1 (en) * | 2014-10-01 | 2018-08-16 | Chien-Hung Chen | Pharmaceutical composition comprising asprin, metformin, and serotonin with non-ionic surfactant |
US10875844B2 (en) | 2015-03-04 | 2020-12-29 | Dana-Farber Cancer Institute, Inc. | Salicylate inhibitors of MELK and methods of use |
US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
WO2019002204A1 (fr) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Système thérapeutique transdermique contenant de l'asénapine et un polymère hybride acrylique de type silicone |
CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
WO2020115765A1 (fr) | 2018-12-05 | 2020-06-11 | Celagenex Research (India) Pvt. Ltd. | Nouvelle composition synergique comprenant des activateurs de sirt1 et d'ampk pour le traitement du syndrome métabolique |
CN115884790A (zh) * | 2020-01-10 | 2023-03-31 | 康圣博施医药有限公司 | 药物的治疗组合以及其使用方法 |
US20220133700A1 (en) * | 2020-10-29 | 2022-05-05 | Thomas Winston | Compositions and methods for treating neurological disorders |
CN115703772A (zh) * | 2021-08-09 | 2023-02-17 | 天地恒一制药股份有限公司 | 艾拉莫德共晶,及其制备方法与应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
US5100919A (en) * | 1984-03-19 | 1992-03-31 | The Rockefeller University | Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein |
US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
GB9311132D0 (en) * | 1993-05-28 | 1993-07-14 | Eisai London Res Lab Ltd | Control of cell death |
DE4409411A1 (de) * | 1994-03-18 | 1995-09-28 | Oped Gmbh Orthopaedische Produ | Verpackungsbehälter |
EP0692252B1 (fr) * | 1994-06-14 | 2001-04-04 | "Raffinerie Tirlemontoise", société anonyme: | Utilisation d'unecomposition contenant de l'inuline ou de l'oligofructose pour le traitement du cancer |
DE9414065U1 (de) | 1994-08-31 | 1994-11-03 | Roehm Gmbh | Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US5981168A (en) * | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
PL351963A1 (en) | 1999-03-19 | 2003-07-14 | Knoll Gmbh | Method of treating eating disorders |
US6589944B1 (en) * | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
US6495538B2 (en) * | 1999-06-23 | 2002-12-17 | Zinc Therapeutics, Canada Inc. | Zinc ionophores as therapeutic agents |
DE19949319A1 (de) | 1999-10-13 | 2001-06-13 | Ruetgers Vft Ag | Verfahren zur Herstellung von Arylalkylethern |
EP1097716A1 (fr) * | 1999-11-03 | 2001-05-09 | Chronolife Inc. | Suppléments de nourriture diététique et médicaments contre l'adiposité à base de l'hormone de libération de la thyrotropine (TRH) |
GB0001449D0 (en) * | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
GB0004003D0 (en) | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
EP1132389A1 (fr) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | Nouveaux dérivés de l'azaindole pour le traitement de l'obésité |
US6670330B1 (en) | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
US6927223B1 (en) * | 2000-05-26 | 2005-08-09 | Washington State University Research Foundation | Use of serotonin agents for adjunct therapy in the treatment of cancer |
ATE305933T1 (de) | 2000-07-31 | 2005-10-15 | Hoffmann La Roche | Piperazin derivate |
YU8803A (sh) * | 2000-08-07 | 2006-01-16 | Ranbaxy Signature L.L.C. | Tečni oblik metformina |
DE60135239D1 (de) | 2000-10-16 | 2008-09-18 | Vernalis Res Ltd | Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden |
WO2002036596A2 (fr) | 2000-11-03 | 2002-05-10 | Wyeth | Cycloalkyl[b][1,4]diazepino[6,7,1-hi]indoles et derives |
WO2002038141A2 (fr) * | 2000-11-08 | 2002-05-16 | Massachusetts Institute Of Technology | Compositions et procedes de traitement de la deficience cognitive legere |
AU2002224266B2 (en) | 2000-11-20 | 2007-05-24 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor |
EP1337518B1 (fr) | 2000-11-20 | 2009-06-17 | Biovitrum AB (publ) | Composes de piperazinylpyrazines utilises comme antagonistes du recepteur de la serotonine 5-ht2 |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
WO2002051844A1 (fr) | 2000-12-27 | 2002-07-04 | F. Hoffmann-La Roche Ag | Derives d'indole et leur utilisation en tant que ligands de recepteurs 5-ht2b et 5-ht2c |
US20020137787A1 (en) * | 2001-03-21 | 2002-09-26 | Geho W. Blair | Prevention or treatment of complications related to non-insulin dependent diabetes mellitus or type 2 diabetes mellitus |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
EP1302465A1 (fr) | 2001-10-11 | 2003-04-16 | BRACCO IMAGING S.p.A. | Amélioration de l'imagerie IRM par le biais d'une fixation réversible à un complexe paramagnétique |
WO2004009017A2 (fr) * | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulateurs de recepteurs de glucocorticoides et procede associe |
US20060147947A1 (en) * | 2002-12-04 | 2006-07-06 | Javier Apfeld | AMPK pathway components |
US20040204472A1 (en) * | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
US7329638B2 (en) * | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
EP1558220B1 (fr) * | 2003-07-24 | 2010-02-10 | Wockhardt Limited | Compositions orales pour le traitement du diabete |
US20050054731A1 (en) | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US20080194019A1 (en) | 2003-09-09 | 2008-08-14 | Beth Israel Deaconess Medical Center, Inc. | Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase |
US7244843B2 (en) * | 2003-10-07 | 2007-07-17 | Bristol-Myers Squibb Company | Modulators of serotonin receptors |
US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
AU2005259864A1 (en) * | 2004-06-30 | 2006-01-12 | Combinatorx, Incorporated | Methods and reagents for the treatment of metabolic disorders |
US20060040980A1 (en) * | 2004-08-20 | 2006-02-23 | Lind Stuart E | Ionophores as cancer chemotherapeutic agents |
EP1789030A2 (fr) | 2004-08-30 | 2007-05-30 | Interstitial Therapeutics | Procédé et préparations pour le traitement de maladies prolifératives |
US20070105790A1 (en) * | 2004-09-02 | 2007-05-10 | Bionaut Pharmaceuticals, Inc. | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors |
WO2006078698A1 (fr) | 2005-01-19 | 2006-07-27 | Cengent Therapeutics, Inc. | Inhibiteurs heterocycliques 2-imidazolone et 2-imidazolidinone de tyrosine phosphatases |
WO2006079021A2 (fr) * | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Methodes et compositions destinees au traitement des bouffees vasomotrices et de la prise de poids d'origine medicamenteuse |
US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
CA2614664A1 (fr) * | 2005-07-14 | 2007-01-25 | Franco Folli | Schema posologique quotidien pour le traitement du diabete, de l'obesite, du syndrome metabolique et du syndrome des ovaires polykystiques |
EP2404604B1 (fr) * | 2006-01-05 | 2019-02-06 | Essentialis, Inc. | Sels d'ouverture de canal ATP du potassium et leurs utilisations |
CA2637027A1 (fr) * | 2006-01-10 | 2007-07-19 | Ruey J. Yu | Acides n-(phosphonoalkyl)-amines, derives, compositions et procedes d'utilisation associes |
KR20080085213A (ko) | 2006-01-12 | 2008-09-23 | 노파르티스 아게 | Mtor 억제제 및 항엽산 화합물의 조합물 |
US7659281B2 (en) * | 2006-04-25 | 2010-02-09 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors |
CA2666036C (fr) * | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Compositions inedites et methodes de traitement des maladies hyperproliferantes |
-
2008
- 2008-01-16 BR BRPI0806774-0A patent/BRPI0806774A2/pt not_active Application Discontinuation
- 2008-01-16 US US12/014,932 patent/US8431552B2/en not_active Expired - Fee Related
- 2008-01-16 MX MX2009007720A patent/MX2009007720A/es unknown
- 2008-01-16 TW TW097101643A patent/TWI440456B/zh not_active IP Right Cessation
- 2008-01-16 DK DK08727718.2T patent/DK2118279T3/en active
- 2008-01-16 NO NO08727718A patent/NO2118279T3/no unknown
- 2008-01-16 NZ NZ578891A patent/NZ578891A/en unknown
- 2008-01-16 MY MYPI20092969A patent/MY154869A/en unknown
- 2008-01-16 SG SG2012003323A patent/SG178716A1/en unknown
- 2008-01-16 WO PCT/US2008/051123 patent/WO2008089212A1/fr active Application Filing
- 2008-01-16 EP EP08727718.2A patent/EP2118279B1/fr active Active
- 2008-01-16 JP JP2009546484A patent/JP5271918B2/ja not_active Expired - Fee Related
- 2008-01-16 AU AU2008206328A patent/AU2008206328B2/en not_active Ceased
- 2008-01-16 EP EP12170283A patent/EP2494967A1/fr not_active Withdrawn
- 2008-01-16 RU RU2009131065/15A patent/RU2486902C2/ru not_active IP Right Cessation
- 2008-01-16 TW TW103110367A patent/TWI629058B/zh not_active IP Right Cessation
- 2008-01-16 CN CN200880005140.0A patent/CN101631859B/zh active Active
- 2008-01-16 ES ES08727718.2T patent/ES2660173T3/es active Active
- 2008-01-16 CA CA2675638A patent/CA2675638C/fr not_active Expired - Fee Related
- 2008-01-16 KR KR1020097016764A patent/KR101460820B1/ko active IP Right Grant
- 2008-01-16 ZA ZA200904972A patent/ZA200904972B/xx unknown
- 2008-01-16 TR TR2018/02359T patent/TR201802359T4/tr unknown
- 2008-01-17 AR ARP080100202A patent/AR065837A1/es not_active Application Discontinuation
-
2009
- 2009-07-16 IL IL199903A patent/IL199903A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN300726577S (zh) | 枕套(豆蔻年华) | |
CN300728365S (zh) | 手电筒(ksl-0527) | |
CN300730341S (zh) | 挂签(原浆经典挂签) | |
CN300728161S (zh) | 刀闸阀(无凹槽) | |
CN300726614S (zh) | 盘子(俏佳人) | |
CN300728490S (zh) | 宠物屋 | |
CN300728675S (zh) | 旅行包(11) | |
CN300728872S (zh) | 椅子(25) | |
CN300728920S (zh) | 餐台(ct838) | |
CN300730360S (zh) | 店牌 | |
CN300729006S (zh) | 随车车载通用衣架 | |
CN300729151S (zh) | 汤锅(直身4) | |
CN300730353S (zh) | 标帖(火腿午餐肉) | |
CN300727858S (zh) | 圆珠笔(社军1) | |
CN300729240S (zh) | 手柄(锯架2) | |
CN300726687S (zh) | 晒物架(旦型3) | |
CN300729435S (zh) | 包装盒(百奇荔枝风味12盒装) | |
CN300729519S (zh) | 包装盒(新快步) | |
CN300730801S (zh) | 蜡烛(14) | |
CN300729574S (zh) | 饼干包装袋(奶香酥) | |
CN300729626S (zh) | 吊卡 | |
CN300727856S (zh) | 笔(k38) | |
CN300729707S (zh) | 首饰链(hy-an0043) | |
CN300726100S (zh) | 扇托(2) | |
CN300728321S (zh) | 隐形纱窗附框 |